Does eradication of Helicobacter pylori impair healing of nonsteroidal anti‐inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
Open Access
- 1 December 1998
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 12 (12) , 1201-1205
- https://doi.org/10.1046/j.1365-2036.1998.00434.x
Abstract
Background: Despite the widely accepted view that Helicobacter pylori is the most important cause of peptic ulcer disease, recent studies have suggested that the microbe protects against nonsteroidal anti‐inflammatory drug (NSAID)‐associated gastroduodenal lesions and promotes ulcer healing. We investigated the effects of H. pylori eradication on the healing of NSAID‐associated bleeding peptic ulcers. Methods: Chronic NSAID users presenting with peptic ulcer haemorrhage underwent endoscopy to secure haemostasis and to document H. pylori infection by rapid urease test and culture. They were prospectively randomized to receive either omeprazole (20 mg once daily) for 8 weeks or a 1‐week course of triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily) for 8 weeks. Endoscopy was repeated after 8 weeks. Final H. pylori status was determined by a 13C‐urea breath test that was performed at least 4 weeks after discontinuation of omeprazole. Results: 195 H. pylori‐infected NSAID users, complicated by bleeding ulcers, were randomized to receive omeprazole alone (102) or triple therapy plus omeprazole (93). 174 patients returned for second endoscopy at 8 weeks (91 in the omeprazole group, 83 in the triple therapy group). Urea breath test was negative in 14% in the omeprazole group vs. 92% in the triple therapy group (P < 0.001). Complete ulcer healing was achieved in 88 (97%) patients in the omeprazole group and 77 (93%) in the triple therapy group (P = 0.31). On intention‐to‐treat analysis, ulcers were healed in 86% of the omeprazole group and 83% of the triple therapy group (P = 0.50). There was no significant difference in the healing rates of gastric or duodenal ulcers between the two groups. Conclusion: Eradication of H. pylori did not impair the healing of NSAID‐associated bleeding peptic ulcers.Keywords
This publication has 17 references indexed in Scilit:
- Failure of Helicobacter pylori eradication to influence site-specific relapse in high risk NSAID users: Results of a large six month double blind randomised controlled clinical trialGastroenterology, 1998
- Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1998
- Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcersThe Lancet, 1997
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.Gut, 1996
- Prevention of Peptic Ulcer and Dyspeptic Symptoms with Omeprazole in Patients Receiving Continuous Non-Steroidal Anti-Inflammatory Drug Therapy: A Nordic Multicentre StudyScandinavian Journal of Gastroenterology, 1996
- Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.Gut, 1995
- Helicobacter pylori in Peptic Ulcer DiseaseJAMA, 1994
- Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.Gut, 1993